News
NBIX
165.31
-1.25%
-2.09
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
NASDAQ · 10h ago
Weekly Report: what happened at NBIX last week (1109-1113)?
Weekly Report · 14h ago
Neurocrine Price Target Raised to $191.00/Share From $185.00 by Morgan Stanley
Dow Jones · 3d ago
Neurocrine Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191
Benzinga · 3d ago
Neurocrine Updates Rare Epilepsy Study as NBI-921352 Trial Ends
TipRanks · 3d ago
Neurocrine Biosciences Shares Rose Even As Profit Fell
Simply Wall St · 3d ago
Neurocrine price target raised to $191 from $185 at Morgan Stanley
TipRanks · 3d ago
Is Ingrezza Quality Of Life Data Altering The Investment Case For Neurocrine Biosciences (NBIX)?
Simply Wall St · 4d ago
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
PR Newswire · 6d ago
Is Neurocrine Biosciences (NBIX) Still Cheap As INGREZZA Data And Earnings Outlook Lift Sentiment?
Simply Wall St · 6d ago
Neurocrine Biosciences Earnings Call Signals Broad Growth
TipRanks · 6d ago
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
NASDAQ · 11/09 16:45
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
NASDAQ · 11/09 16:00
NBIX vs. GRDN: Which Stock Is the Better Value Option?
NASDAQ · 11/09 15:40
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?
NASDAQ · 11/09 13:55
The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business
Simply Wall St · 11/09 10:06
Weekly Report: what happened at NBIX last week (1102-1106)?
Weekly Report · 11/09 09:17
Analysts Have Conflicting Sentiments on These Healthcare Companies: NexImmune (OtherNEXI), Legend Biotech (LEGN) and Neurocrine (NBIX)
TipRanks · 11/06 07:20
Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules
Benzinga · 11/05 13:37
More
Webull provides a variety of real-time NBIX stock news. You can receive the latest news about Neurocrine Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.